

Please complete each section of the referral form below and fax to OptiMed along with a copy (front and back) of all the patient's pharmacy and medical insurance cards, the patient's demographic face sheet, and any relevant clinical notes/documents.

Prescriber Information	Prescriber: _____ NPI: _____ Phone: _____ Fax: _____ Office Contact: _____ Address: _____					
Patient Information	Name: _____ DOB: _____ <input type="checkbox"/> M <input type="checkbox"/> F Address: _____ Phone: _____ 2nd Phone: _____ SSN: _____ Primary Language: _____ Functional Limitations: _____					
Clinical Information	Diagnosis (include ICD-10 code): _____ Weight: _____ <input type="checkbox"/> lb <input type="checkbox"/> kg Height: _____ <input type="checkbox"/> in IV access: <input type="checkbox"/> PIV <input type="checkbox"/> PICC <input type="checkbox"/> Port <input type="checkbox"/> Other: _____ Patient's first dose? <input type="checkbox"/> Yes <input type="checkbox"/> No; date of last dose _____ Prior infusion reactions: _____ Allergies: _____ Latex allergy? <input type="checkbox"/> Yes <input type="checkbox"/> No Prior treatments & reason for discontinuation: _____ <hr/> History of kidney disease: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, SCr: _____ GFR/CrCl: _____ History of heart failure: <input type="checkbox"/> Yes <input type="checkbox"/> No <hr/> REQUIRED G6PD deficiency: <input type="checkbox"/> Yes <input type="checkbox"/> No Latest serum uric acid (sUA): _____ Prescriber is responsible for ensuring the patient has orders for pre-infusion serum uric acid to be drawn within 48 hours prior to each Krystexxa™ infusion. ^ For streamlined communications, please request the lab to share results with OptiMed. <i>^If sUA level is > 6mg/dL, consider discontinuing treatment, particularly when two consecutive sUA levels > 6mg/dL are observed.</i>					
Prescription Information	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 80%; text-align: center;">Krystexxa™ Dosing Regimen</th> <th style="width: 20%; text-align: center;">Quantity</th> </tr> </thead> <tbody> <tr> <td> <input type="checkbox"/> Dosing: Infuse Krystexxa™ 8mg in 250mL NaCl 0.9% IV every 2 weeks, infused over no less than 2 hours (Infuse rate not to exceed 125mL/h)* *If serum uric acid > 6mg/dL after first infusion of Krystexxa™, hold dosing unless explicit consent is received from the ordering provider to continue treatment. </td> <td style="text-align: center; vertical-align: bottom;"> _____ doses (infusions) </td> </tr> </tbody> </table> <p>Nursing and Supplies: OptiMed to provide additional supply items and nursing care to prepare and administer product as per package instructions.</p> <p>Premedication(s):</p> <ul style="list-style-type: none"> • Methylprednisolone 80mg IV 30 minutes prior to Krystexxa™ infusion • Acetaminophen 1000mg PO 30 minutes prior to Krystexxa™ infusion • Diphenhydramine 50mg IV 30 minutes prior to Krystexxa™ infusion <p>Additional premedication(s): _____</p> <p>PRN medication orders: _____</p> <p>Post-Infusion: Patient to receive post-infusion monitoring and hydration with 500mL NaCl 0.9% infused over 60 minutes following each Krystexxa™ infusion.</p> <p>Lab orders: List any additional outpatient laboratory work related to this therapy you would like OptiMed to draw in conjunction with the patient's medication administration, including the frequency for each lab order. (Lab orders are subject to availability.)</p>		Krystexxa™ Dosing Regimen	Quantity	<input type="checkbox"/> Dosing: Infuse Krystexxa™ 8mg in 250mL NaCl 0.9% IV every 2 weeks, infused over no less than 2 hours (Infuse rate not to exceed 125mL/h)* *If serum uric acid > 6mg/dL after first infusion of Krystexxa™, hold dosing unless explicit consent is received from the ordering provider to continue treatment.	_____ doses (infusions)
Krystexxa™ Dosing Regimen	Quantity					
<input type="checkbox"/> Dosing: Infuse Krystexxa™ 8mg in 250mL NaCl 0.9% IV every 2 weeks, infused over no less than 2 hours (Infuse rate not to exceed 125mL/h)* *If serum uric acid > 6mg/dL after first infusion of Krystexxa™, hold dosing unless explicit consent is received from the ordering provider to continue treatment.	_____ doses (infusions)					
Prescriber Signature	My signature for this prescription also confirms that the treatment(s) indicated on this referral is/are medically necessary. I authorize OptiMed and its representatives to act as an agent of mine to initiate and execute the patient's insurance prior authorization process and to provide administrative nursing services and supplies in conjunction with the therapy prescribed above. Signature: _____ Date: _____					